Business Trends Impacting the Health Care Marketplace

[B2] Brand and Generic Drugs in Development

ACPE UAN: 0233-0000-19-024-L04-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

• 

  Jeffrey Casberg, MS, RPh

  Director of Pharmacy
  IPD Analytics, LLC
  Old Saybrook, Connecticut
• 

  Leslie Fish, RPh, PharmD

  Director of Pharmacy
  IPD Analytics, LLC
  Worcester, Massachusetts

Moderator(s)

• RF

  Renee Rizzo Fleming, RPh, MBA

  President
  PRN Managed Care Consulting Services, LLC
  East Amherst, New York

This session focuses on new and emerging brand-name drugs, as well as upcoming generic drug approvals. You will hear about the most promising agents moving through the pipeline, their projected time to market and potential litigation delays, as well as their potential value and role in therapy, and likely implications for managed care pharmacy.

Learning Objectives:

At the completion of this activity, participants should be able to:

1. Identify high impact brand and generic drugs that are recently approved or likely to emerge from the pharmaceutical pipeline in the coming year.
2. Describe the mechanism of action and expected indications of promising agents in the pipeline.
3. Outline considerations for drug choices within respective therapeutic classes.
4. Discuss the litigation potentially affecting high impact pipeline drugs release dates.
5. Report the expected impact of new generic drug approvals on the managed care market.